Takeda‘s Oranienburg location – center of excellence for fixed forms in the worldwide production network The CoLaborator from Bayer provides the perfect environment for young companies in the life sciences. Biotech Analyticon Discovery BIOTECON Diagnostics Co.don Epigenomics Glycotope Ifp Institut für Produktqualität In.vent DIAGNOSTICA InVivo Biotech Services JPT Peptide Technologies KNAUER Wissenschaftliche Geräte LGC metanomics MOLOGEN NOXXON Pharma Omeicos Therapeutics Organobalance ProBioGen Seramun Diagnostica SGS INSTITUT FRESENIUS Berlin SIFIN Silence Therapeutics Thermo Fisher Scientific – B·R·A·H·M·S TIB MOLBIOL For a complete overview of all the companies, see our Life Sciences Report. Leading European location for biotechnology Biotechnology is an engine of innovation in the Berlin-Brandenburg region. The sector is recording steady growth and a high rate of company startups. This positive trend is based on the region’s excellent research landscape and technology parks specialized in biotechnology. They provide optimal conditions for startups and large, research-intensive companies alike. Of the more than 240 biotechnology companies with approx. 5,000 employees here, 80% focus on biomedicine. They develop innovative therapeutic and diagnostic procedures for the treatment of cancer, cardiovascular diseases and diabetes, and benefit from the region‘s excellent science and top infrastructure for clinical studies. Berlin- Brandenburg possesses expertise in genome and proteome research, diagnostics, regenerative medicine, RNA technologies and glyco- engineering technology. »The Berlin-Brandenburg metropolitan area is a unique place inside the German healthcare sector. Nowhere else in Germany will you find a comparable concentration of world class science, hospitals and industry. This cross-functional cluster turns the German capital region into a true magnet for healthcare investments in Europe.« Stefan Oelrich Member of the Board of Management President Pharmaceuticals Bayer AG »The technology for our innovative vaccines originated at the Max Planck Institute of Colloids and Interfaces which is located in the greater Berlin area. So it was natural to locate Vaxxilon in the region. We received excellent support from the Adlershof Technology Park to establish our offices and laboratories.« Dr. Claney Pereira General Manager Vaxxilon Deutschland GmbH Pharmaceutical location with a rich history and modern dynamics The sustained success of pharmaceutical industry in Berlin and Brandenburg is based on innovative products and a venerable tradition reaching back to the 19th century. The sector benefits from an excellent scientific environment and clinical research landscape, and its proximity to the health care system decision makers. This applies to global players such as Bayer, Pfizer, Sanofi, Takeda and Berlin-Chemie (Menarini) and to more than 20 additional medium-sized pharmaceuticals companies with a total of 10,000 employees. Many international corporations such as Daiichi Sankyo and Astra Zeneca also have representative offices in Berlin. Bayer can look back at a long history in Berlin. Today, the company is one of the world‘s leading speciality pharmaceuticals companies. More than 1,000 Sanofi employees manage the company‘s marketing and sales activities in Berlin. In 2011, Takeda Pharma took over the Nycomed Group and only one year later, moved its sales headquarters to Berlin. Takeda is currently investing €100 million to expand its production facilities in Oranienburg.
Leading German biotechnology location with over 240 companies in the sector Pharmaceutical location with a rich history Outstanding conditions for clinical research Excellent access to skilled specialists due to the many degree, training and continuing education programs Outstanding science landscape featuring Charité – Universitätsmedizin Berlin and many other university and non-university research institutions (Max Planck, Fraunhofer and Leibniz Institutes and the Helmholtz Centers) Political center and seat of the vfa, BPI and BIO Deutschland sector associations, as well as health insurance companies and patient organisations Production of biomarkers at B.R.A.H.M.S GmbH in Hennigsdorf Tight network among science and business through interdisciplinary partnerships in the areas of biotechnology, diagnostics, pharmaceuticals, medical technology, photonics and ICT Pharmaceutical giant Pfizer is also expanding its activities in the capital region, establishing other business units to supplement its German headquarters here. For example, the company manages its oncology business unit for Europe from Berlin. In 2014 Riemser Pharma reinforced its sales activities with an operations-related unit in Berlin. In 2015 Boehringer Ingelheim opened a representative office in the capital. Berlin-Chemie is investing € 80 million to expand its production facilities in the south of Berlin. Dr. Kade, which has been growing in the capital region for over 25 years, has taken over Takeda‘s OTC business. And the fact that Klosterfrau Berlin invested in a new production hall also shows that Berlin has developed into an important production location in recent years. Clinical research The close connection between research, development and the clinics here is most obviously demonstrated by the region‘s successful, well-established translational research and the wide range of opportunities available for implementing clinical studies. With its large, extremely diverse patient collective, Berlin- »We founded OMEICOS Therapeutics on the base of research results, generated at the Max-Delbrück- Center for Molecular Medicine. Our continuous close collaboration with MDC and other partners in Berlin is of great value for OMEICOS’ success. As pioneers in the field of synthetic omega-3 epoxyeicosanoid analogs, we are developing small molecules for cardiovascular and ophthalmic indications.« Dr. Karen Uhlmann Director Legal Corporate & Operations OMEICOS Therapeutics GmbH »The Berlin-Brandenburg region is a leading location for healthcare in Germany. The proximity to science and research, and also to health policy actors, make it the ideal location for our sales center and one of our production facilities. In producing and distributing mostly speciality drugs, we employ over 1,000 workers and trainees in Berlin and Brandenburg.« Günter Kloucek CEO Takeda Pharma Vertrieb GmbH & Co. KG Brandenburg facilitates all kinds of clinical research projects. Charité – Universitätsmedizin Berlin and CROs such as Parexel – active with over 1,000 employees in Berlin – and other smaller providers that supervise studies of all types all play outstanding roles in this area. Optimal conditions for startups The nine biotechnology parks in the region provide optimal conditions for young, growing companies. Over 50% of the biotechnology companies use the programs of the stateowned or privately operated parks, which offer a variety of contextual focal areas. In addition to the availability of laboratory space and an extensive technical infrastructure, they benefit from the close contact and intense exchange with the research institutions and multi- faceted service providers that are also located in the parks. When it comes to early stage financing, the states‘ own business development banks have investment companies whose technology funds play an important role. Projects such as Bayer‘s CoLaborator are evidence of the major pharmaceuticals corporations‘ involvement. Pharma Aenova / Haupt Pharma Berlin Aristo Pharma Bausch + Lomb Bayer Berlin-Chemie (Menarini Group) DR. KADE Pharmazeutische Fabrik Klosterfrau Berlin Merz Pharmaceuticals Next Pharma Pfizer Riemser Pharma Sanofi Shire Takeda Pharma Networks BioResponse Network DiagnostikNet-BB glyconet Berlin Brandenburg NetPhaSol Biotech-Parks berlinbiotechpark Biotech Campus Potsdam Biotechnologiepark Luckenwalde Campus Berlin-Buch co:bios Technologiezentrum Hennigsdorf GO:IN Golm Innovationszentrum, Potsdam Science and Technology Park Adlershof Techno Terrain Teltow Wuhlheide Innovation Park